Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

March 17, 2023

Conditions
Parkinson's Disease
Interventions
DRUG

ABBV-951

Continuous Subcutaneous Infusion (CSCI)

Trial Locations (10)

20007

Georgetown University Hospital /ID# 230224, Washington D.C.

60612

Rush University Medical Center /ID# 229983, Chicago

78746

Parkinson Disease Movement Disorders Clinic /ID# 245791, Austin

80045

University of Colorado Hospital /ID# 229974, Aurora

84132

University of Utah Health Care /ID# 241219, Salt Lake City

27612-8106

Carolina Phase 1, LLC /ID# 239836, Raleigh

74136-6378

The Movement Disorder Clinic of Oklahoma /ID# 238610, Tulsa

37232-0011

Vanderbilt University Medical Center /ID# 230255, Nashville

78628-4126

Texas Movement Disorder Specialists /ID# 238607, Georgetown

77030-3411

Baylor College of Medicine - Baylor Medical Center /ID# 239631, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY